Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients

NCT07007052 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Interventions

DRUG: Venetoclax
DRUG: Tagraxofusp

Sponsor

French Innovative Leukemia Organisation

Collaborators

[object Object]
[object Object]